Compassionate Use of Letermovir in a 2-Year-Old Immunocompromised Child With Resistant Cytomegalovirus Disease.
Détails
Demande d'une copie Sous embargo indéterminé.Accès restreint UNIL
Etat: Public
Version: Final published version
Licence: Non spécifiée
ID Serval
serval:BIB_34AA25DDD16D
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Etude de cas (case report): rapporte une observation et la commente brièvement.
Collection
Publications
Institution
Titre
Compassionate Use of Letermovir in a 2-Year-Old Immunocompromised Child With Resistant Cytomegalovirus Disease.
Périodique
Journal of the Pediatric Infectious Diseases Society
ISSN
2048-7207 (Electronic)
ISSN-L
2048-7193
Statut éditorial
Publié
Date de publication
28/02/2020
Peer-reviewed
Oui
Volume
9
Numéro
1
Pages
96-99
Langue
anglais
Notes
Publication types: Case Reports ; Journal Article
Publication Status: ppublish
Publication Status: ppublish
Résumé
Little information on the efficacy and pharmacokinetics of letermovir among immunocompromised children is currently available. We describe here the use of letermovir in a 2-year-old immunocompromised child with ganciclovir-resistant cytomegalovirus disease who required extracorporeal membrane oxygenation. Detailed information on therapeutic-drug-monitoring measures and dosage adjustments for letermovir is provided.
Mots-clé
Acetates/administration & dosage, Acetates/pharmacokinetics, Acetates/therapeutic use, Antiviral Agents/administration & dosage, Antiviral Agents/pharmacokinetics, Antiviral Agents/therapeutic use, Child, Preschool, Compassionate Use Trials, Cytomegalovirus/genetics, Cytomegalovirus/isolation & purification, Cytomegalovirus Infections/drug therapy, Cytomegalovirus Infections/immunology, Cytomegalovirus Infections/virology, DNA, Viral/blood, Dose-Response Relationship, Drug, Drug Monitoring/methods, Extracorporeal Membrane Oxygenation/adverse effects, Fatal Outcome, Female, Ganciclovir/therapeutic use, Hepatitis, Viral, Human/drug therapy, Hepatitis, Viral, Human/immunology, Humans, Immunocompromised Host, Opportunistic Infections/drug therapy, Pneumonia, Viral/drug therapy, Pneumonia, Viral/immunology, Pneumonia, Viral/virology, Polymerase Chain Reaction, Quinazolines/administration & dosage, Quinazolines/pharmacokinetics, Quinazolines/therapeutic use, Treatment Failure, Viral Load, cytomegalovirus disease, cytomegalovirus infection, letermovir, therapeutic drug monitoring
Pubmed
Web of science
Création de la notice
18/06/2019 9:11
Dernière modification de la notice
21/10/2023 7:07
Données d'usage
